Health Economics›Breast cancer›HER2-positive subsequent lines of therapy

HER2-positive subsequent lines of therapy

Breast cancer · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Trastuzumab deruxtecan monotherapy Variant #01	—	R 81 019	21d	15.5 mo	23.4 mo	23	R 1 863 446 PFS proxy	9
Capecitabine and Lapatinib Variant #01	—	R 24 534	21d	6.8 mo	21.6 mo	10	R 245 345 PFS proxy	7
Capecitabine and Trastuzumab (XH) Variant #02	—	R 11 671	21d	5.0 mo	22.7 mo	8	R 93 364 PFS proxy	8
Capecitabine and Trastuzumab (XH) and Tucatinib Variant #01 Partial	—	R 11 424	21d	7.6 mo	23.3 mo	12	R 137 087 PFS proxy	3

4 of 4 regimens shown